Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 47

1.

Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer.

Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F, Wallace TA, Liu CG, Volinia S, Calin GA, Yfantis HG, Stephens RM, Croce CM.

Cancer Res. 2008 Aug 1;68(15):6162-70. doi: 10.1158/0008-5472.CAN-08-0144.

2.

GOLPH2 and MYO6: putative prostate cancer markers localized to the Golgi apparatus.

Wei S, Dunn TA, Isaacs WB, De Marzo AM, Luo J.

Prostate. 2008 Sep 15;68(13):1387-95. doi: 10.1002/pros.20806.

3.

Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer.

Setlur SR, Mertz KD, Hoshida Y, Demichelis F, Lupien M, Perner S, Sboner A, Pawitan Y, Andrén O, Johnson LA, Tang J, Adami HO, Calza S, Chinnaiyan AM, Rhodes D, Tomlins S, Fall K, Mucci LA, Kantoff PW, Stampfer MJ, Andersson SO, Varenhorst E, Johansson JE, Brown M, Golub TR, Rubin MA.

J Natl Cancer Inst. 2008 Jun 4;100(11):815-25. doi: 10.1093/jnci/djn150. Epub 2008 May 27.

4.

SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines.

Demichelis F, Greulich H, Macoska JA, Beroukhim R, Sellers WR, Garraway L, Rubin MA.

Nucleic Acids Res. 2008 Apr;36(7):2446-56. doi: 10.1093/nar/gkn089. Epub 2008 Feb 27.

5.

Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer.

Helgeson BE, Tomlins SA, Shah N, Laxman B, Cao Q, Prensner JR, Cao X, Singla N, Montie JE, Varambally S, Mehra R, Chinnaiyan AM.

Cancer Res. 2008 Jan 1;68(1):73-80. doi: 10.1158/0008-5472.CAN-07-5352.

6.

Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma.

Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D, Vivanco I, Lee JC, Huang JH, Alexander S, Du J, Kau T, Thomas RK, Shah K, Soto H, Perner S, Prensner J, Debiasi RM, Demichelis F, Hatton C, Rubin MA, Garraway LA, Nelson SF, Liau L, Mischel PS, Cloughesy TF, Meyerson M, Golub TA, Lander ES, Mellinghoff IK, Sellers WR.

Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):20007-12. Epub 2007 Dec 6.

7.

EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patients.

Laitinen S, Martikainen PM, Tolonen T, Isola J, Tammela TL, Visakorpi T.

Int J Cancer. 2008 Feb 1;122(3):595-602.

8.

Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis.

Lapointe J, Li C, Giacomini CP, Salari K, Huang S, Wang P, Ferrari M, Hernandez-Boussard T, Brooks JD, Pollack JR.

Cancer Res. 2007 Sep 15;67(18):8504-10.

9.

c-Maf interacts with c-Myb to down-regulate Bcl-2 expression and increase apoptosis in peripheral CD4 cells.

Peng S, Lalani S, Leavenworth JW, Ho IC, Pauza ME.

Eur J Immunol. 2007 Oct;37(10):2868-80.

10.

FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome.

Yoshimoto M, Cunha IW, Coudry RA, Fonseca FP, Torres CH, Soares FA, Squire JA.

Br J Cancer. 2007 Sep 3;97(5):678-85. Epub 2007 Aug 14.

11.

Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer.

Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS, Menon A, Jing X, Cao Q, Han B, Yu J, Wang L, Montie JE, Rubin MA, Pienta KJ, Roulston D, Shah RB, Varambally S, Mehra R, Chinnaiyan AM.

Nature. 2007 Aug 2;448(7153):595-9.

12.

Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer.

Attard G, Clark J, Ambroisine L, Fisher G, Kovacs G, Flohr P, Berney D, Foster CS, Fletcher A, Gerald WL, Moller H, Reuter V, De Bono JS, Scardino P, Cuzick J, Cooper CS; Transatlantic Prostate Group.

Oncogene. 2008 Jan 10;27(3):253-63. Epub 2007 Jul 16.

13.

Systematic prediction and validation of breakpoints associated with copy-number variants in the human genome.

Korbel JO, Urban AE, Grubert F, Du J, Royce TE, Starr P, Zhong G, Emanuel BS, Weissman SM, Snyder M, Gerstein MB.

Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10110-5. Epub 2007 Jun 5.

14.

Chromosomal aberrations in prostate cancer.

Saramaki O, Visakorpi T.

Front Biosci. 2007 May 1;12:3287-301.

PMID:
17485299
15.

Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model.

Mertz KD, Setlur SR, Dhanasekaran SM, Demichelis F, Perner S, Tomlins S, Tchinda J, Laxman B, Vessella RL, Beroukhim R, Lee C, Chinnaiyan AM, Rubin MA.

Neoplasia. 2007 Mar;9(3):200-6.

16.

Assessing the need for sequence-based normalization in tiling microarray experiments.

Royce TE, Rozowsky JS, Gerstein MB.

Bioinformatics. 2007 Apr 15;23(8):988-97. Epub 2007 Mar 25.

PMID:
17387113
17.

Morphological features of TMPRSS2-ERG gene fusion prostate cancer.

Mosquera JM, Perner S, Demichelis F, Kim R, Hofer MD, Mertz KD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, Rubin MA.

J Pathol. 2007 May;212(1):91-101.

18.

TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort.

Demichelis F, Fall K, Perner S, Andrén O, Schmidt F, Setlur SR, Hoshida Y, Mosquera JM, Pawitan Y, Lee C, Adami HO, Mucci LA, Kantoff PW, Andersson SO, Chinnaiyan AM, Johansson JE, Rubin MA.

Oncogene. 2007 Jul 5;26(31):4596-9. Epub 2007 Jan 22. Erratum in: Oncogene. 2007 Aug 16;26(38):5692.

PMID:
17237811
19.

Migrating with myosin VI.

Knudsen B.

Am J Pathol. 2006 Nov;169(5):1523-6. No abstract available.

20.

TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer.

Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM, Setlur S, Tchinda J, Tomlins SA, Hofer MD, Pienta KG, Kuefer R, Vessella R, Sun XW, Meyerson M, Lee C, Sellers WR, Chinnaiyan AM, Rubin MA.

Cancer Res. 2006 Sep 1;66(17):8337-41.

Supplemental Content

Support Center